Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis

被引：17
|
作者：
Liu, Yan Ping [3 ]
Hao, Pan Pan [1 ,2 ]
Zhang, Ming Xiang [1 ,2 ]
Zhang, Cheng [1 ,2 ]
Gao, Fei [1 ,2 ]
Zhang, Yun [1 ,2 ]
Chen, Yu Guo [1 ,2 ]
机构：
[1] Shandong Univ, Qilu Hosp, Chinese Minist Educ, Key Lab Cardiovasc Remodeling & Funct Res, Jinan 250012, Peoples R China
[2] Shandong Univ, Qilu Hosp, Chinese Minist Publ Hlth, Jinan 250012, Peoples R China
[3] Shandong Univ, Sch Med, Inst Expt Nucl Med, Jinan 250012, Peoples R China
来源：
THROMBOSIS RESEARCH | 2011年 / 128卷 / 06期
关键词：
PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; STENT THROMBOSIS; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; TREATED PATIENTS; RISK; GENOTYPE; CYP2C19-ASTERISK-2; ACTIVATION;
D O I：
10.1016/j.thromres.2011.07.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：593 / 594
页数：2
相关论文
共 50 条
  • [41] Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis
    Xie, Qiufen
    Xiang, Qian
    Liu, Zhiyan
    Mu, Guangyan
    Zhou, Shuang
    Zhang, Zhuo
    Ma, Lingyue
    Gong, Yanjun
    Jiang, Jie
    Cui, Yimin
    BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
  • [42] Cyp2c19 Polymorphisms Are Not Associated With the Longterm Clinical Outcomes in Stroke Patients Treated With Clopidogrel
    Tanaka, Tomotaka
    Yamagami, Hiroshi
    Ihara, Masafumi
    Hamasaki, Toshimitsu
    Miyata, Shigeki
    Miyata, Toshiyuki
    Yamamoto, Haruko
    Toyoda, Kazunori
    Nagatsuka, Kazuyuki
    STROKE, 2016, 47
  • [43] Clopidogrel and CYP2C19 Testing: Ready for Clinical Prime Time?
    Hulot, Jean-Sebastien
    Hajjar, Roger
    Montalescot, Gilles
    CLINICAL CHEMISTRY, 2012, 58 (01) : 154 - 157
  • [44] The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy
    Tatarunas, Vacis
    Kupstyte-Kristapone, Nora
    Norvilaite, Rita
    Tamakauskas, Vytenis
    Skipskis, Vilius
    Audrone, Veikutiene
    Jurgaityte, Julija
    Stuoka, Mantvydas
    Lesauskaite, Vaiva
    PHARMACOGENOMICS, 2019, 20 (07) : 483 - 492
  • [45] Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
    Sibbing, D.
    Gebhard, D.
    Koch, W.
    Braun, S.
    Stegherr, J.
    Morath, T.
    Von Beckerath, N.
    Mehilli, J.
    Schoemig, A.
    Schuster, T.
    Kastrati, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (08) : 1685 - 1693
  • [46] Influence of Smoking on CYP2C19 Genetic Variants and Clopidogrel Efficacy in Patients with Minor Stroke or TIA.
    Wang, Tingting
    Pan, Yuesong
    Lin, Jinxi
    Anand, Raja
    Johnston, S. Claiborne
    Wang, Yongjun
    Wang, Yilong
    STROKE, 2019, 50
  • [47] Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms
    Chen, B. L.
    Chen, Y.
    Tu, J. H.
    Li, Y. L.
    Zhang, W.
    Li, Q.
    Fan, L.
    Tan, Z. R.
    Hu, D. L.
    Wang, D.
    Wang, L. S.
    OuYang, D. S.
    Zhou, H. H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (05): : 574 - 581
  • [48] ASSOCIATION OF CYP2C19*2 TO ALTERED CLOPIDOGREL REACTIVITY AS MEASURED BY A POINT-OF-CARE ANALYSIS
    So, Derek Yiu Fai
    Szymanska, Irena
    Stewart, Alex
    Le May, Michel
    Labinaz, Marino
    Goncalves, Sandro
    Assogba, Olivia
    Glover, Chris
    Dandona, Sonny
    Roberts, Robert
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [49] CYP2C19 GENETIC VARIATION AND INDIVIDUALIZED CLOPIDOGREL PRESCRIPTION IN A CARDIOLOGY CLINIC
    Mirabbasi, S. A.
    Khalighi, K.
    Khalighi, B.
    Kodali, A.
    Wu, Y.
    Fan, W.
    CARDIOLOGY, 2016, 134 : 242 - 242
  • [50] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
    Boulenc, Xavier
    Djebli, Nassim
    Shi, Juan
    Perrin, Laurent
    Brian, William
    Van Horn, Robert
    Hurbin, Fabrice
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 187 - 197
12345